18 results on '"Bogaerts, Jan"'
Search Results
2. Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting
3. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer
4. ‘Mind the gap’ between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research
5. Societal challenges of precision medicine: Bringing order to chaos
6. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
7. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology
8. Societal challenges of precision medicine: Bringing order to chaos
9. RECIST 1.1—Update and clarification: From the RECIST committee
10. RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
11. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
12. Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative
13. The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database
14. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community
15. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
16. Individual patient data analysis to assess modifications to the RECIST criteria
17. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group
18. The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.